Byotrol secures US retail trial with Target

AIM-quoted anti-microbial technology company Byotrol has secured a mass market retail trial in the US for its 24-hour germ-kill surface sanitizer Byotrol24.

The trial, due to take place over a 10-12 week period, will see Byotrol24 made available on the shelves of national retailer Target.

Byotrol expects the trial to start in June, making the product immediately available at approximately 10% of Target's 1,829 stores in North America.

Following the trial, Target will then decide whether it wishes to roll-out Byotrol24 into nationwide distribution.

Byotrol completed individual US State product registration earlier in May and received formal approval from the US Environmental Protection Agency for Byotrol24 in June 2017.

David Traynor, chief executive of Byotrol, said, "This is really good news for Byotrol. Target Corporation is one of the leading general merchandise retailers in the US and is well-known for innovation and design; it is a perfect retail match for our brand and an excellent first step in pursuing our US commercialisation ambitions."

As of 0845 BST, Byotrol shares had shot up 14.03% to 4.39p.